Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation

Endocrinology. 2000 Nov;141(11):4146-55. doi: 10.1210/endo.141.11.7793.

Abstract

It was previously demonstrated that insulin or TSH treatment of FRTL-5 cells resulted in an elevation of glucose transport and in an increase of cell surface expression of the glucose transporter Glut-1. However, the signaling mechanisms leading to the insulin or TSH-induced increase in the cell surface expression of Glut-1 were not investigated. In the present study, we demonstrated that wortmannin and LY294002, two specific inhibitors of phosphatidylinositol 3-kinase (PI3-kinase), interfere both in the signaling pathways of insulin and TSH leading to glucose consumption enhancement and Glut-1 translocation. Two hours after insulin treatment, TSH or cAMP analog (Bu)2cAMP stimulation, glucose transport was increased and most of the intracellular Glut-1 pool was translocated to plasma membranes. Wortmannin or LY294002 blocked the insulin, (Bu)2cAMP, and the TSH-induced translocation of Glut-1. Wortmannin or LY294002 alone did not alter the basal ratio between intracellular and cell surface Glut-1 molecules. These results suggest that in FRTL-5 cells wortmannin and LY294002 inhibited the insulin, (Bu)2cAMP and TSH events leading to Glut-1 translocation from an intracellular compartment to the plasma membrane. Likewise, (Bu)2cAMP effects on glucose transport and Glut-1 translocation to plasma membrane were repressed by PI3-kinase inhibitors but not by the protein kinase A (PKA) inhibitor H89. We suggest that (Bu)2cAMP stimulates Glut-1 translocation to plasma membrane through PI3-kinase-dependent and PKA-independent signaling pathways. To further elucidate mechanisms that regulate the translocation of Glut-1 to cell membrane, we extended this study to the role played by the N-glycosylation in the translocation and in the biological activity of Glut-1 in FRTL-5 cells. For this purpose we used tunicamycin, an inhibitor of the N-glycosylation. Our experiments with tunicamycin clearly showed that both the glycosylated and unglycosylated forms of the transporter reached the cell surface. Likewise, a decrease in glucose consumption (-50%) after treatment of cells with tunicamycin was accompanied by a decrease (-70% vs. control) in the membrane expression of a 50-kDa form of Glut-1 and an increase in its unglycosylated 41-kDa form. These results suggest that carbohydrate moiety is essential for the biological activity of glucose transport but is not required for the translocation of Glut-1 from the intracellular membrane pool to the plasma membrane.

MeSH terms

  • Androstadienes / pharmacology
  • Animals
  • Biological Transport / drug effects
  • Bucladesine / pharmacology
  • Cell Line
  • Chromones / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Enzyme Inhibitors / pharmacology
  • Gene Expression / drug effects
  • Glucose / metabolism
  • Glucose Transporter Type 1
  • Glycosylation*
  • Insulin / pharmacology
  • Isoquinolines / pharmacology
  • Monosaccharide Transport Proteins / genetics
  • Monosaccharide Transport Proteins / metabolism*
  • Morpholines / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Rats
  • Sulfonamides*
  • Thyroid Gland / drug effects
  • Thyroid Gland / metabolism*
  • Thyrotropin / pharmacology
  • Tunicamycin / pharmacology
  • Wortmannin

Substances

  • Androstadienes
  • Chromones
  • Enzyme Inhibitors
  • Glucose Transporter Type 1
  • Insulin
  • Isoquinolines
  • Monosaccharide Transport Proteins
  • Morpholines
  • Phosphoinositide-3 Kinase Inhibitors
  • Slc2a1 protein, rat
  • Sulfonamides
  • Tunicamycin
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • Bucladesine
  • Thyrotropin
  • Cyclic AMP-Dependent Protein Kinases
  • Glucose
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Wortmannin